This was the stock's fourth consecutive day of gains.

Several companies on Wall Street have seen recent Seeking Alpha analyst activity, including both upgrades and downgrades.

The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

DekaBank Deutsche Girozentrale increased its stake in Regeneron Pharmaceuticals by 4.7% this quarter, now holding 221,176 ...

The Paroxysmal Nocturnal Hemoglobinuria treatment market is experiencing significant expansion, driven by increasing disease awareness, rising preval ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.